BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, has announced the launch of its protein Barcoding Kit designed to transform protein research by empowering researchers with an advanced multiplexed protein screening solution.

The protein Barcoding Kit offers a multiplexed solution for efficient protein screening using peptide barcodes, tailored to the needs of biopharma research. It supports critical applications such as optimizing lipid nanoparticle (LNP), evaluating mRNA therapeutics, and analyzing protein characteristics.

The kit reduces time and costs through streamlined workflows while delivering relative quantitation across a broad dynamic range. With an overnight workflow that requires less than an hour of hands-on time, it is designed to be sensitive enough to detect low-abundance proteins, providing researchers with an innovative tool for therapeutic development.

"We believe Quantum-Si's protein Barcoding Kit represents a groundbreaking leap forward in protein research, combining multiplexed precision with effortless workflows to transform how biopharma tackles complex challenges. By enabling faster, more cost-effective analysis of protein and drug delivery systems, this innovation paves the way for breakthroughs in therapeutic development," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si.

For more information about Quantum-Si's innovative solutions, visit .

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company, is focused on revolutionizing the growing field of proteomics. The Company's Platinum instrument enables Next-Gen Protein Sequencing that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company's ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum protein sequencing instrument and kits and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com